Mass General Brigham Ventures invests exclusively in health care sector companies based on intellectual property created within our own research community.
We find and invest in new ventures based on novel life science technologies emerging from Mass General Brigham’s world-class research community, the largest medical research engine in the United States. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.
When we invest, we support our portfolio companies through their entire financing lifecycles. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies.
Mass General Brigham’s academic hospitals and Harvard Medical School faculty and more than 6,000 investigators serve as primary sources of intellectual capital assets for venture investments with more than $2 billion in federal funding annually. Our teams of investigators bring forth new and effective ways to diagnose, prevent, and cure disease every day. We work side-by-side with our scientific founders to build companies around innovative science and to provide the early-stage care and feeding necessary to thrive. Today, we manage three funds with more than $450 million in capital from both internal and external sources.
Our unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. With visibility and access to Mass General Brigham's vast intellectual property estate, we have a privileged position to originate new ventures that advance novel medicines.
Mass General Brigham hospitals share a legacy of innovation that includes 18 Nobel laureates and the development of therapies that have redefined the contemporary standard of care. The scope of the research enterprise is rooted in leadership and innovation spanning more than 150 years, as Mass General Brigham hospitals have been home to many of the world’s most notable medical advances.
Mass General Brigham is a widely acknowledged academic leader in scientific and clinical research. Our hospitals boast a history of medical firsts, including the use of TNF fusion protein for the treatment of rheumatoid arthritis (Enbrel®); elucidation of PD-1 receptor biology that spawned the field of immuno-oncology therapy; the discovery of CRISPR gene-editing technology; and the targeting of EGFR gene mutations that enable high-efficacy personalized lung cancer therapy.
Below is just a further sampling of the hundreds of products, discoveries, and best practices originating at Mass General Brigham hospitals, where a culture of innovation is ingrained in their missions: